

Pavel Moudry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3103537/publications.pdf>

Version: 2024-02-01

10
papers

1,260
citations

1163117

8
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

2844
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. <i>Nature</i> , 2017, 552, 194-199. | 27.8 | 516 |
| 2 | High speed of fork progression induces DNA replication stress and genomic instability. <i>Nature</i> , 2018, 559, 279-284. | 27.8 | 374 |
| 3 | Impaired ribosome biogenesis: mechanisms and relevance to cancer and aging. <i>Aging</i> , 2019, 11, 2512-2540. | 3.1 | 129 |
| 4 | Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. <i>Cell Cycle</i> , 2012, 11, 1573-1582. | 2.6 | 81 |
| 5 | TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity. <i>Journal of Cell Biology</i> , 2016, 212, 281-288. | 5.2 | 70 |
| 6 | Perturbation of RNA Polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells. <i>Cell Cycle</i> , 2018, 17, 92-101. | 2.6 | 30 |
| 7 | Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells. <i>Journal of Proteomics</i> , 2017, 162, 73-85. | 2.4 | 28 |
| 8 | Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity. <i>Oncotarget</i> , 2015, 6, 10746-10758. | 1.8 | 16 |
| 9 | RNA-interference screen for p53 regulators unveils a role of WDR75 in ribosome biogenesis. <i>Cell Death and Differentiation</i> , 2021, , . | 11.2 | 10 |
| 10 | A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. <i>Cell Death and Disease</i> , 2022, 13, 203. | 6.3 | 6 |